Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective i…
Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday. The vaccine was 72% effective against moderate and severe disease in the US, the company said. It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna that have been shown to be about 95% effective against symptomatic disease. But experts say the Johnson & Johnson vaccine would be a useful tool that can reduce strain on health care systems and prevent hospitalization and death.
(📸: Michael Ciaglo/Getty Images)
Credit to the Original Source